Thelansis

Glioblastoma (GBM) Market Access and Reimbursement Insights Thelansis’s “Glioblastoma (GBM) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve market access Pricin...

Glioblastoma (GBM) Emerging Therapy and TPP Insights Thelansis’s “Glioblastoma (GBM) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attribu...

Glioblastoma (GBM) Market Outlook Thelansis’s “Glioblastoma (GBM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glioblastoma (GBM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What in...

Glioblastoma (GBM) Market Access and Reimbursement Insights Thelansis’s “Glioblastoma (GBM) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Glioblastoma (GBM) Overview Glioblastoma (GBM) is the most aggressive type of diffuse glioma, originating from the astrocytic lineage. It ranks as the most prevalent malignant primary brain tumor, comprising 54% of all gliomas and 16% of primary brain tumors. GBM is classified as a malignant astrocytic tumor, earning a Grade IV designation according to the WHO classification. The exact cause of this disease remains unknown, except in cases where it emerges following therapeutic b...

Glioblastoma (GBM) Emerging Therapy and TPP Insights Thelansis’s “Glioblastoma (GBM) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Glioblastoma (GBM) Overview Glioblastoma (GBM) is the most aggressive type of diffuse glioma, originating from the astrocytic lineage. It ranks as the most prevalent malignant primary brain tumor, comprising 54% of all gliomas and 16% of primary brain tumors. GBM is classified as a malignant astrocytic tumor, earning a Grade IV designation according to the WHO classification. The exact cause of this disease remains unknown, except in cases where it emerges following therapeutic brain irradiation for other conditions. The genetic anomalies identified, such as EGFR gene amplificat...

  Glioblastoma (GBM) Market Outlook Thelansis’s “Glioblastoma (GBM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glioblastoma (GBM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Glioblastoma (GBM) Overview Glioblastoma (GBM) is the most aggressive type of diffuse glioma, originating from the astrocytic lineage. It ranks as the most prevalent malignant primary brain tumor, comprising 54% of all gliomas and 16% of primary brain tumors. GBM is classified as a malignant astrocytic tumor, earning a Grade IV designation according to the WHO classification. The exact cause of this disease remains unknown, except in cases where it...

  Glioblastoma (GBM) is the most aggressive among the diffuse gliomas originating from the astrocytic lineage. It ranks as the most prevalent malignant primary brain tumor, comprising 54% of all gliomas and 16% of primary brain tumors. GBM is classified as a malignant astrocytic tumors, earning a Grade IV designation according to the WHO classification. The exact cause of this disease remains unknown, except in cases where it emerges following therapeutic brain irradiation for other conditions. The genetic anomalies identified, such as EGFR gene amplification (7p12), TP53 gene mutations (17p13.1), and chromosome 10 loss, vary depending on the tumor's nature: primary glioblastoma (de novo) or secondary glioblastoma (arising from a benign astrocytic tumor). Glioblastomas can develop at any age. They are most commonly observed in patients between 45 and 70, making up 70% of cases in this age group. Typically, these tumors are situated in the brain hemispheres but can occur throughout ...

  Glioblastoma (GBM) is the most aggressive diffuse glioma of the astrocytic lineage. It is the most common malignant primary brain tumor making up 54% of all gliomas and 16% of all primary brain tumors. GBM treatment is complex, initially consisting of maximally safe surgical resection followed by radiation therapy (RT) and concurrent Temozolomide (TMZ) chemotherapy. Glioblastoma has an incidence of 2 to 3.4 per 1,00,000 population in the US and Europe. Thelansis’s “Glioblastoma (GBM) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glioblastoma (GBM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Gli...

Glioblastoma (GBM) is the most aggressive diffuse glioma of astrocytic lineage and is the most common malignant primary brain tumor making up 54% of all gliomas and 16% of all primary brain tumors. GBM treatment is complex, initially consisting of maximally safe surgical resection followed by radiation therapy (RT) and concurrent Temozolomide (TMZ) chemotherapy.  GBM comprised of primary and secondary types, constituting distinct disease entities which evolve through different genetic pathways, affect patients at different ages, and likely differ in prognosis and response to therapy.  Primary de novo GBM accounts for more than 80% of GBM (6), occurs in older patients (mean age = 64 years), and typically shows epidermal growth factor receptor (EGFR) over expression, PTN (MMC I) mutation, CDKN2A (p16) deletion, and less frequently MDM2 amplification.    Epidemiology- Glioblastoma has an incidence of 2 to 3.4 per 100,000 population in US and Europe.   The competiti...